This could potentially be due to the design of the antibodies, as magrolimab also has specific toxicities such as RBC agglutination leading to anemia [10, 13, 64, 65], a concern that was absent with SRF231 and other newer CD47 mAbs [18, 74]. The gene discussed is CD47; the disease is anemia.